# A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

> **NCT05279300** · PHASE1 · RECRUITING · sponsor: **CStone Pharmaceuticals** · enrollment: 480 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Advanced Lymphoma

## Interventions

- **DRUG:** CS5001
- **BIOLOGICAL:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Lenalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05279300
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279300, "A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT05279300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*